BNR (Burning Rock Biotech) Total Liabilities: $39.37 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BNR Burning Rock Biotech Ltd BNR
61 GF Score
Price $9.40
GF Value $7.47
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Burning Rock Biotech Total Liabilities?

Burning Rock Biotech BNR +0.53% 61 Total Liabilities is $39.37 Mil as of Mar. 2026. GuruFocus rates BNR with a GF Score™ of 61/100 and a GF Value™ of $7.47 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Burning Rock Biotech's Total Liabilities for the quarter that ended in Mar. 2026 was $39.37 Mil.

Burning Rock Biotech's quarterly Total Liabilities increased from Sep. 2025 ($36.86 Mil) to Dec. 2025 ($40.48 Mil) but then declined from Dec. 2025 ($40.48 Mil) to Mar. 2026 ($39.37 Mil).

Burning Rock Biotech's annual Total Liabilities increased from Dec. 2023 ($38.04 Mil) to Dec. 2024 ($41.82 Mil) but then declined from Dec. 2024 ($41.82 Mil) to Dec. 2025 ($40.48 Mil).

Burning Rock Biotech Total Liabilities Historical Data

* Premium members only.

The historical data trend for Burning Rock Biotech's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Burning Rock Biotech Total Liabilities Chart

Burning Rock Biotech Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only 68.03 61.55 38.04 41.82 40.48

Burning Rock Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.03 36.31 36.86 40.48 39.37
BNR
61GF Score
Burning Rock Biotech Ltd BNR
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Burning Rock Biotech Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Burning Rock Biotech's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=35.066+(3.714+1.7
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=40.48

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=116.478-75.997
=40.48

Burning Rock Biotech's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=33.345+(4.288+1.735
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=39.37

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=114.302-74.935
=39.37

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $39.37 Mil mean?
Burning Rock Biotech (BNR) has a Total Liabilities of $39.37 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Burning Rock Biotech and its competitors.
Is Burning Rock Biotech's Total Liabilities too high?
Burning Rock Biotech's current Total Liabilities is $39.37 Mil. Overall, Burning Rock Biotech has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Burning Rock Biotech's Total Liabilities compare to XGN and IDXG?
Burning Rock Biotech's Total Liabilities of $39.37 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Diagnostics & Research company?
A good Total Liabilities depends on the Medical Diagnostics & Research industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Burning Rock Biotech and its competitors. Burning Rock Biotech's current Total Liabilities is $39.37 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Burning Rock Biotech stock overvalued right now?
Based on GuruFocus' analysis, Burning Rock Biotech (BNR) is currently considered Modestly Overvalued. The stock's GF Value™ is $7.47, compared to a current price of $9.40 — trading 25.8% above its estimated fair value. The current Total Liabilities is $39.37 Mil. Burning Rock Biotech's overall GF Score™ is 61/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Burning Rock Biotech (BNR), the current Total Liabilities is $39.37 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Burning Rock Biotech (BNR) Overvalued in 2026?

Based on GuruFocus' analysis, Burning Rock Biotech stock appears to be overvalued. The current stock price of $9.40 is trading 25.8% above its estimated GF Value™ of $7.47. GuruFocus considers Burning Rock Biotech to be Modestly Overvalued.

Key valuation signals for BNR:

  • Total Liabilities: $39.37 Mil
  • GF Value™: $7.47 vs. price of $9.40 (25.8% above fair value)
  • GF Score™: 61/100 with 2 warning signs

No single metric tells the full story. See the BNR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Burning Rock Biotech Business Description

Other Exchanges 6BU0:Germany
Address No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, CHN, 510005
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.
61GF Score

Get the complete analysis for BNR

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.40
Price
$7.47
GF Value